循环microRNA-95在前列腺癌早期精准诊断和预后判断中的作用
| 作者: |
1肖春玲,
2朱进,
1王苏贵
1 徐州医科大学附属淮安医院泌尿外科，江苏 淮安 223002 2 苏州大学附属第二医院泌尿外科，江苏 苏州 215004 |
| 通讯: |
王苏贵
Email: wangsugui107@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.12.005 |
| 基金: | 江苏省“六大人才高峰”项目(2019-WSW-218)；淮安市自然科学基金(HAB201730)；徐州医科大学附属淮安医院科研基金(YK201506)。 |
摘要
目的：探讨循环microRNA(以下简称miR-95)在前列腺癌早期精准诊断和预后判断中的作用。方法：通过qPCR检测60例前列腺癌患者、60例前列腺增生患者及60例健康男性血清miR-95的相对表达水平，分析血清miR-95的相对表达水平与临床病理特征的关系，并构建受试者工作特征(receiver operating characters，ROC)曲线，分析血清miR-95对于前列腺癌诊断的敏感度和特异度。结果：前列腺癌患者血清miR-95的表达水平较前列腺增生及健康男性增高，差异有统计学意义(P<0.05)，而前列腺增生患者血清miR-95的表达水平和健康男性中的表达无明显统计学差异(P>0.05)。血清miR-95表达水平与前列腺癌临床病理分期、Gleason评分及骨转移显著相关(P<0.05)；与年龄、前列腺特异性抗原水平无关(P>0.05)。ROC曲线显示miR-95能够较好的区分前列腺癌与前列腺增生及健康男性，曲线下面积分别为0.826(95%CI：0.792~0.918)和0.808(95%CI：0.745~0.919)。结论：miR-95在前列腺癌患者血清中高表达，与前列腺癌进展有关，有望作前列腺癌早期精准诊断和预后的标志物。
关键词：
miR-95；血清；前列腺癌
Role of circulating microRNA-95 in early accurate diagnosis and prognosis of prostate cancer
CorrespondingAuthor: WANG Sugui Email: wangsugui107@163.com
DOI: 10.3978/j.issn.2095-6959.2019.12.005
Foundation: This work was supported by the Six Talents Peak Programs in Jiangsu Province (2019-WSW-218), Natural Science Foundation of Huai’an (HAB201730) and Scientific Research Project of Huaian Hospital Affiliated to Xuzhou Medical University (YK201506)
Abstract
Objective: To investigate the role of circulating microRNA-95 in early accurate diagnosis and prognosis of prostate cancer. Methods: qPCR was used to detect the relative expression level of serum microRNA-95 in 60 patients with prostate cancer, 60 patients with benign prostatic hyperplasia and 60 healthy men. The relationship between the relative expression level of serum microRNA-95 and clinicopathological characteristics was analyzed. The ROC curve was constructed to analyze the sensitivity and specificity of serum microRNA-95 in the diagnosis of prostate cancer. Results: The expression level of serum microRNA-95 in prostate cancer patients was higher than that in benign prostatic hyperplasia and healthy men (P<0.05), but there was no significant difference in the expression level of serum microRNA-95 between benign prostatic hyperplasia patients and healthy men (P>0.05). Serum level of microRNA-95 was significantly correlated with clinical pathological stage, Gleason score and bone metastasis of prostate cancer (P<0.05), but not with age and prostate specific antigen (P>0.05). ROC curve showed that microRNA-95 could differentiate prostate cancer from benign prostatic hyperplasia and healthy males. The area under the curve was 0.826 (95% CI: 0.792–0.918) and 0.808 (95% CI: 0.745–0.919), respectively. Conclusion: The high expression of microRNA-95 in the serum of prostate cancer patients is related to the progression of prostate cancer, and it is expected to be a marker of early accurate diagnosis and prognosis of prostate cancer.
Keywords：
microRNA-95; serum; prostate cancer